Full Press Release Details
FLORHAM PARK, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences:
2023 Jefferies Healthcare Conference in New York City, NY, with a scheduled fireside chat on Wednesday, June 7, 2023, at 1:30 p.m. EDT. Management will also participate in one-on-one meetings throughout the conference, which runs from June 7-9, 2023.
44th Annual Goldman Sachs Global Healthcare Conference in Dana Point, CA, with a scheduled fireside chat on Wednesday, June 14, 2023, at 11:00 a.m. EDT. Management will also participate in one-on-one meetings throughout the conference, which runs from June 12-15, 2023.
To access the live webcast and archived recordings of the fireside chats, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recordings will be available for 90 days following each event.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.
Tags
gastrointestinal disease